Transcript
Page 1: *Significant favorable factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs

Factors β 95% CI P-valueTRECs1 m MA 0.224 (0.034– 0.592) 0.028*

Younger donor age (BM) 0.356 (0.191– 1.150) 0.007*3 m Younger recipient age 0.243 (0.046– 0.781) 0.028*

Younger donor age (BM) 0.555 (0.623– 1.689) 0.000*Relation 0.222 (0.007– 0.710) 0.045*

6 m Younger recipient age 0.342 (0.277– 1.595) 0.006*No chronic GVHD 0.498 (0.714–1.880) 0.000*

1 y Younger recipient age 0.584 (0.922– 2.301) 0.000*PID 0.366 (0.221– 1.809) 0.013*Younger donor age (BM) 0.532 (0.504–3.417) 0.011*BM (compared with CB) -0.356 (-1.865– -0.150) 0.023†No chronic GVHD 0.467 (0.527– 2.041) 0.001*

2 y Younger recipient age 0.707 (0.974– 2.592) 0.000*PID 0.584 (0.567– 2.500) 0.003*

sjKRECs1 m Younger donor age (BM) 0.396 (0.187– 0.833) 0.003*

BM (compared with CB) -0.252 (-0.772– -0.075) 0.018†3 m Younger recipient age 0.233 (0.048– 1.287) 0.035*

Younger donor age (BM) 0.425 (0.445– 2.132) 0.004*BM (compared with CB) -0.272 (-1.325– 0.117) 0.020†Grade 0–2 aGVHD 0.370 (0.485–1.984) 0.002*No chronic GVHD 0.392 (0.478–1.538) 0.000*No use of PSL/HDC 0.309 (0.246– 1.334) 0.005*

6 m Younger recipient age 0.423 (0.522– 1.794) 0.001*MA 0.316 (0.192– 1.466) 0.012*Younger donor age (BM) 0.448 (0.257–2.369) 0.017*Grade 0–2 aGVHD 0.320 (0.209– 2.065) 0.017*No chronic GVHD 0.281 (0.085– 1.378) 0.027*No use of ATG 0.339 (0.285– 1.730) 0.007*

1 y Younger recipient age 0.492 (0.462– 1.567) 0.001*PID 0.329 (0.080– 1.277) 0.027*PB (compared with CB) -0.469 (-2.884– -0.102) 0.037†Grade 0–2 aGVHD 0.436 (0.396– 2.220) 0.006*No chronic GVHD 0.501 (0.477– 1.587) 0.001*

2 y Younger recipient age 0.632 (0.475– 1.669) 0.001*PID 0.459 (0.099–1.523) 0.028*Younger donor age (BM) 0.761 (0.493– 2.266) 0.007*BM (compared with CB) -0.593 (-1.381– -0.291) 0.005†PB (compared with CB) -0.701 (-3.087– -0.406) 0.016†Grade 0–2 aGVHD 0.682 (0.701–2.544) 0.002*No chronic GVHD 0.447 (0.070– 1.447) 0.032*

Supplementary Table II. Univariate analysis of factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs.

*Significant favorable factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs.†Significant unfavorable factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs.

Factors β 95% CI P-valuecjKRECs1 m Younger donor age (BM) 0.353 (0.190– 1.185) 0.008*3 m Younger recipient age 0.224 (0.023– 1.405) 0.043*

MA 0.239 (0.063– 1.338) 0.032*Younger donor age (BM) 0.525 (0.936– 2.793) 0.000*BM (compared with CB) -0.326 (-1.672– -0.312) 0.005†Grade 0–2 aGVHD 0.310 (0.301– 2.023) 0.009*No chronic GVHD 0.392 (0.532– 1.714) 0.000*No use of PSL/HDC 0.297 (0.235– 1.447) 0.007*

6 m Younger recipient age 0.451 (0.673– 2.058) 0.000*MA 0.252 (0.012– 1.449) 0.046*Younger donor age (BM) 0.422 (0.191– 2.657) 0.025*PB (compared with CB) -0.438 (-2.473– -0.329) 0.012†Grade 0-2 of aGVHD 0.267 (0.004– 2.091) 0.049*No chronic GVHD 0.332 (0.256– 1.658) 0.008*No use of ATG 0.295 (0.158– 1.779) 0.020*

1 y Younger recipient age 0.459 (0.414– 1.630) 0.002*Younger donor age (BM) 0.466 (0.101– 1.647) 0.029*BM (compared with PB) 0.377 (0.033–2.091) 0.044*Grade 0–2 aGVHD 0.414 (0.358– 2.429) 0.010*No chronic GVHD 0.358 (0.149– 1.447) 0.017*

2 y PID 0.505 (0.171– 1.352) 0.014*BM (compared with CB) -0.478 (-0.790– -0.050) 0.028†PB (compared with CB) -0.722 (-3.091– -0.499) 0.012†BM (compared with PB) 0.620 (0.280–2.470) 0.018*Grade 0–2 aGVHD 0.659 (0.551– 2.236) 0.003*No chronic GVHD 0.493 (0.143– 1.287) 0.017*